-
What MS experts have to say about Ocrevus a year after its approval
A year after U.S. regulators approved Genentech’s Ocrevus as the first treatment for both the relapsing and progressive forms of multiple sclerosis, a prominent neurologist involved in the clinical trials that led to its authorization says it has been beneficial for some MS patients. However, it’s still too early to tell if the infusion therapy is the game changer it’s developers predicted it could be for the MS population in general.
Read more about experts opinions on Ocrevus and how this treatment can benefit patients, here: “Ocrevus a Year After Approval: Views of Some MS Experts”
Are you being treated for RPMS with Ocrevus? Share your experience below!
-
0 Replies
Sorry, there were no replies found.
Log in to reply.